What are they doing?, page-16

IMO ATHE is developing a safe iron chelator, PBT434 and trying to demonstrate that it works in MSA and so get it to the market after phase II study now in the optimizing phase.
I have posted here on this board papers demonstrating that iron chelator could have positive effects in several diseases as:
- PD
- AD
- MSA
- sarcopenia
- vascular diseases (endothelial damage )
- atrial fibrillation ??
- depression
- diabetic neuropathy
- anxiety
- heart failure
- traumatic encephalopathy
- epilepsy
- metabolic syndrome
- optic neuropathy
- macular degeneration
- myelodysplastic syndrome
- atherosclerosis
- brain hemorrhage
- stroke
- any nerve injury
- etc.

I am sure there are a few more diseases in which a safe iron chelator could work. But today we do not know if PBT434 works, as at least I would hope, in all these problems. It has been a long time to wait for these steps needed to prove PBT434. At least I am still here to see if ATHE will get PBT434 to the market. If that does not happen I can not blame management if I lose money, only my self. But if PBT434 works ..... that is a new story in medicine. That is why Sinclair is on the board.